Vaccine Expert Says Pause In Johnson & Johnson COVID 19 Study Is Not Unusual

loading...

A University of Pittsburgh expert on vaccine research says the pause in a Johnson & Johnson clinical trial of a potential COVID-19 vaccine after a participant became sick is not unusual.

"Because this is happening under a global microscope, we hear, we want to know, and we ask the question, 'What does that mean?'" Dr. Paul Duprex, director of the Center for Vaccine Research at the University of Pittsburgh, told Pittsburgh's Action News 4.

Sign up for our Newsletters

Duprex understands public interest in the pause in Johnson & Johnson's COVID-19 vaccine clinical trial. Pitt and UPMC hadn't been a part of the Johnson & Johnson study but anticipates it will be. UPMC and the University of Pittsburgh School of Medicine are continuing their work on a potential COVID-19 vaccine. The university's Center For Vaccine Research works with them and also collaborates with other researchers around the world.

"Pauses in a clinical trial are very very common. They happen often (and) this is just part of the process of how clinical trials are run," Duprex said.

With word of the unexplained illness of one participant, Duprex said an independent review is automatically launched.

"A committee pulled together. They will look at 'Did the person receive the vaccine, did the person get the placebo, what type of adverse affect was it? How long did it last?'" he said.

Duprex says that with the study this large, unrelated incidents are a possibility.

"Just because people have had illnesses does not mean that the vaccine that is being tested in 60,000 people caused that illness," Duprex said.

He suggests thinking of in terms of what could happen in a neighborhood that size.

"This is double the population of East Liberty in Pittsburgh. And it would not surprise you in East Liberty that there are many people that have illnesses," Duprex said.

Duprex says the pause in the Johnson & Johnson trial to look closer at what happened shows the process is working -- and demonstrates people are not rushing.

"I think it's very important to have these conversations, so that we can reassure the public that this is normal. That this is the way it should be," Duprex said.

On Sept. 23, Johnson and Johnson started enrolling 60,000 volunteers for its Phase 3 study in the U.S., Argentina, Brazil, Chile, Columbia, Mexico, Peru, and South Africa.

The projected eight to 12 month timeline of federal health officials for development of a vaccine is still underway.

TOP STORIES FROM WTAE:

Watch Live: Day 2 of confirmation hearings for Amy Coney Barrett

Three students test positive for COVID-19 at Greater Latrobe Senior High School, school to remain open

Allegheny County Common Pleas Court Judge John Zottola dies

Pennsylvania has 174,646 coronavirus cases

Coronavirus in Western Pa.: Over 24,000 cases in 14 counties, according to state Health Dept.

READ THE FULL STORY: > Pitt vaccine expert says pause in Johnson & Johnson COVID-19 study is not unusual

CHECK OUT WTAE: > Stay in the know with the latest Pittsburgh news, weather and sports. Catch all of the day’s top stories and more from the team at WTAE Pittsburgh Action News 4.

Source : https://www.msn.com/en-us/news/us/pitt-vaccine-expert-says-pause-in-johnson-johnson-covid-19-study-is-not-unusual/ar-BB19Zl6b

Pitt vaccine expert says pause in Johnson & Johnson COVID-19 study is not unusual
Coronavirus live news: WHO says foreign experts to go to China soon; US tops 10,000 weekly deaths
Coronavirus updates: Third vaccine candidate up to 90% effective; November infections explode; Thanksgiving travel continues to surge
Coronavirus updates: Third vaccine candidate up to 90% effective; White House sticks with holiday party plans; November infections up
J&J says review of illness that led to pause of coronavirus vaccine trial could take days
AstraZeneca, Johnson & Johnson coronavirus vaccine trials set to resume
Johnson & Johnson Pauses COVID-19 Vaccine Trial. What's Next?
A week after Covid-19 vaccine trial goes on pause, Johnson & Johnson and FDA won't reveal critical details
Halting of Eli Lilly coronavirus drug trial more concerning than other 2 trial delays, experts say
Vaccine expert says pause in Johnson & Johnson COVID-19 study is not unusual
[LIMITED STOCK!] Related eBay Products